We at CFIF often highlight the clear and present danger that drug price control schemes pose to American…
CFIF on Twitter CFIF on YouTube
New Lung Cancer Breakthrough Illustrates the Potential Peril of Drug Price Controls

We at CFIF often highlight the clear and present danger that drug price control schemes pose to American consumers, who benefit from our private pharmaceutical sector that leads the world - by far - in innovation.  A new lung cancer treatment breakthrough in the form of Amgen's Lumakras illustrates that interrelationship.

Simply put, Lumakras reduced the risk of progression by 34% compared to chemotherapy in patents with advanced lung cancer, which is particularly welcome considering lung cancer's especially low survival rate (18.6% over five years, and just 5% for advanced forms).  The breakthrough required years of research and enormous amounts of investment, however, which The Wall Street Journal notes makes Lumakras the type of innovation put at risk by new drug price controls…[more]

September 22, 2022 • 05:06 PM

Liberty Update

CFIFs latest news, commentary and alerts delivered to your inbox.
Jester's Courtroom Legal tales stranger than stranger than fiction: Ridiculous and sometimes funny lawsuits plaguing our courts
Home Jester's Courtroom Brand Name Drug Makers Held Liable for Generic Drug Label Warnings
Brand Name Drug Makers Held Liable for Generic Drug Label Warnings Print
Thursday, September 04 2014

The Alabama Supreme Court recently upheld an earlier decision that found the makers of brand-name drugs liable for the warning labels on the generic version of their drugs.

Citing the theory of innovator liability, the Alabama Supreme Court ruled that, even if the plaintiff only used the generic brand, the brand-name drug maker had potential liability since generic drug makers must provide an exact copy of the warning labels on the brand-name drugs they copy. 

Alabama is the first state to find brand-name drug manufacturers potentially liable.

In 2011, the U.S. Supreme Court decided in Pliva v. Mensing that generic drug makers cannot be held liable through “failure to warn” lawsuits, since such claims are pre-empted by federal requirements that prevent the manufacturers from providing different warnings than are provided on the brand-name version.

According to news reports, the FDA is in the process of finalizing new generic drug label requirements.

Source: aboutlawsuits.com

Quiz Question   
Which one of the following U.S. Presidents signed the executive order establishing the Federal Emergency Management Agency (FEMA)?
More Questions
Notable Quote   
 
"Now they tell us. We're referring to the Congressional Budget Office, which finally rolled in Monday with its cost estimate for President Biden's unilateral student-loan write-down: $420 billion. ...The cost of Mr. Biden's unilateral extension of the moratorium on student loan payments for another three months through December will be $20 billion. But that's a bargain compared to the $400 billion…[more]
 
 
—The Wall Street Journal Editorial Board
— The Wall Street Journal Editorial Board
 
Liberty Poll   

Choosing from the list below, what issue is currently most important to you heading into the mid-term elections?